Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (798)	1/14/2000 6:28:00 PM
From: aknahow	Respond to of 3158

I agree. If they merge, they become less able to deal with picking up another entity, in part because they are going to be dealing with making the two companies fit together, rationalization etc. Also in part because they will feel they have already accomplished/consumated something and probably not be ready to go through more of the same at the moment. At any rate here is another article. cbs.marketwatch.com

To: Biomaven who wrote (798)	1/14/2000 8:08:00 PM
From: Larry Liebman	Read Replies (1) \| Respond to of 3158

Were I shopping for a nice biotech to munch, I would be actively performing due diligence on ALXN and NBIX. Heck, a 1 point move in AMGN is equivalent to the capitaliztion of both companies combined. I've actually been surprised that there haven't been more MLNM/LKST deals. I anticipate that mega-bio's, i.e., BGEN, AMGN, MLNM, GENZ, IMNX, etc., may shop 'til they drop, ultimately becoming the 21st century big pharmas.